Disarming dendritic cells: A tumor strategy to escape from immune control

Expert Review of Clinical Immunology

Volumn 3, Issue 3, 2007, Pages 411-422

  Della Bella, Silvia ^a   Clerici, Mario ^a   Villa, Maria Luisa ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antitumor immunity; Cancer immunotherapy; Cellular vaccine; Dendritic cell; Immune escape; Immune modifier; Tumor

Indexed keywords

CANCER VACCINE; COLONY STIMULATING FACTOR 1; CYTOKINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; PROSTANOID; TUMOR ANTIGEN; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; LYMPHATIC SYSTEM DISEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR ESCAPE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION;

EID: 34249690149     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.3.411     Document Type: Review

References (79)

1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727 (2006).
2. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66(11), 5527-5536 (2006).
3. Adams S, O'Neill DW, Bhardwaj N. Recent advances in dendritic cell biology. J. Clin. Immunol. 25(3), 177-188 (2005).
4. Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J. Immunol. 175, 1373-1381 (2005).
5. Skoberne M, Beignon AS, Bhardway N. Danger signals: a time and space continuum. Trends Mol. Med. 10 (6), 251-257 (2004).
6. Reis e Sousa C. Dendritic cells in a mature age. Nat. Rev. Immunol. 6, 476-483 (2006).
7. Gilboa E. The promise of cancer vaccines. Nat. Rev. Cancer 4, 401-411 (2004).
8. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat. Immunol. 6, 107-113 (2005).
9. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer. Res. 92, 13-27 (2004)
10. Bonasio R, von Andrian UH. Generation, migration and function of circulating dendritic cells. Curr. Opin. Immunol. 18, 503-511 (2006).
11. Della Bella S, Gennaro M, Vaccari M et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89(8), 1463-1472 (2003).
12. + immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia 7(12), 1112-1122 (2005).
13. Della Porta M, Danova M, Rigolin GM et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 68(2-3), 276-284 (2005).
14. + (myeloid) in prostate adenocarcinoma patients. Prostate 67, 1-7 (2007).
15. Della Bella S, Nicola S, Brambilla L et al. Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin. Immunol. 119(3), 317-329 (2006).
16. Hasskamp JH, Elias EG, Zapas JL. In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma. J. Clin. Immunol. 26(4), 331-338 (2006).
17. Mohty M, Jarrossay D, Lafage-Pochitaloff M et al. Circulating blood dendritic cells from myeloid leukaemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98(13), 3750-3756 (2001).
18. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myelorna: the role of interleukin-6. Blood 100(1), 231-237 (2002).
19. - primitive haematopoietic progenitors. Br. J. Haematol. 119, 115-118 (2002).
20. Ben Mami N, Molity M, Chambost H, Gaugler B, Olive D. Blood dendritic cells in patients with acute lymphoblastic leukaemia. Br. J. Haematol. 126, 77-80 (2004)
21. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 63, 4497-4506 (2003).
22. Huang A, Gilmour JW, Imami N, Amjadi P, Henderson DC, Allen-Mersh TG. Increased serum transforming growth factor-β1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. Clin. Exp. Immunol. 134, 270-278 (2003).
23. Reichert TE, Scheuer C, Wagner W, Whiteside TL. The number of intraturnoral dendritic cells and ξ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91, 2136-2147 (2001).
24. Yilmaz T, Gedikoglu G, Celik A, Onerci M, Turan E. Prognostic significance of Langerhans cell infiltration in cancer of the larynx. Otolaryngol. Head Neck Surg. 132, 309-316 (2005).
25. Ishigami S, Natsugoe S, Matsumoto M et al. Clinical implication of antitumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol. Rep. 10, 1237-1240 (2003).
26. Tsujitani S, Furukawa T, Tamada R, Okamura T, Yasumoto K, Sugimachi K. Langerhans cells and prognosis in patients with gastric carcinoma. Cancer 59, 501-505 (1987).
27. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Cancer 63, 496-503 (1989).
28. Schwaab T, Weiss JE, Schned AR, Barth RJ. Dendritic cell infiltration in colon cancer. J. Immunother. 24, 130-137 (2001).
29. Lespagnard L, Gancberg D, Rouas G et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and clinical outcome. Int. J. Cancer 84, 309-314 (1999).
30. Tsukayama S, Omura K, Yoshida K, Tanaka Y, Watanabe G. Prognostic value of CD83-posirive mature dendritic cells and their relation to vascular endothelial grow factor in advanced human gastric cancer. Oncol. Rep. 14, 369-375 (2005).
31. Van Gisbergen KPJM, Aarnoudse CA, Meijer GA, Geijtenbeek TBH, van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecular-3-grabbing nonintegrin. Cancer Res. 65, 5935-44 (2005).
32. Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190, 1417-1425 (1999).
33. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4(3), 585-593 (1998).
34. Shurin GV, Ferris R, Tourkova IL et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174, 5490-5498 (2005).
35. Zou W, Machelon V, Coulomb-U Hermin A et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 12, 1339-1346 (2001).
36. Curiel TJ, Cheng P, Mottram P et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64, 5535-5538 (2004).
37. + regulatory T cells in human ovarian carcinoma. Cancer Res. 65, 5020-5026 (2005).
38. Hartmann E, Wollenberg B, Rothenfusser S et al. Identification ad functional analysis of tumor-in filtrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63, 6478-6487 (2003).
39. Treilleux I, Blay JY, Bendriss-Vermare N et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10, 7466-7474 (2004).
40. Molenkamp BG, van Leeuwen PA, van den Eertwegh AJM et al. Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option. Immunobiology 211(6-8), 651-661 (2006).
41. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SPL, Essner R. Tumor-induced immune modulation of sentinel lymph nodes. Nat. Rev. Immunol. 6, 659-670 (2006).
42. Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Merastasis Rev. 25, 233-242 (2006).
43. Cox K, North M, Burke M et al. Plasmacytoid dendritic cells (PDC) are the major DC subset innately producing cytokines in human lymph nodes. J. Leukoc. Biol. 78, 1142-1152 (2005).
44. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000).
45. Ito M, Minamiya Y, Kawai H et al. Tumor-derived TGF-β induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 176, 5637-5643 (2006).
46. Sakakura K, Chimatsu K, Sakurai T et al. Infiltration of dendritic cells and NK cells into the sentinel lymph node in oral cavity cancer. Oral Oncol. 41, 89-96 (2005).
47. Tsujitani S, Oka A, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Infiltration of dendritic cells into regional lymph nodes in gastric cancer. Cancer 75, 1478-1483 (1995).
48. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 163-274 (2005).
49. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Rev. Immunol. 2, 293-299 (2001).
50. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12, 33-42 (2002).
51. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
52. Pinzon-Charry A, Maxwell T, Lopez A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell Biol. 83, 451-461 (2005).
53. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93 (5), 1634-1642 (1999).
54. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6, 613-625 (2006).
55. + hemopoietic progenitors. J. Immunol. 157(4), 1499-1507 (1996).
56. Geissmann F, Revy P, Repault A et al. TGF-2b 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162(8), 4567-4575 (1999).
57. Denkerr C, Kobel M, Berger S et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 61 (1), 303-308 (2001).
58. Sombroek CC, Stain AG, Masterson AJ et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168(9), 4333-4443 (2002).
59. Kryczek I, Lange A, Mottram P et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65, 465-472 (2005).
60. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 78(12), 1573-1577 (1998).
61. Riboldi E, Musso T, Moroni E et al. Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol. 175, 2788-2792 (2005).
62. + progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92(12), 4778-4791 (1998).
63. Hayashi T, Hideshima T, Akiyama M et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 102(4), 1435-1442 (2003).
64. McCarter M, Clarke J, Richter D, Wilson C. Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 138, 321-328 (2005).
65. Mohty M, Olive D, Gaugler B. Plasmacytoid DCs and cancer: a new role for an enigmatic cell. Trends Immunol. 25(8), 397-398 (2004).
66. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol. Med. 10, 15-18 (2004).
67. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin. Invest. 114, 280-290 (2004).
68. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104, 2235-2246 (2004).
69. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
70. Adema GJ, de Vries JM, Punt CJA, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol. 17, 170-174 (2005).
71. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumor prevention. Nat. Rev. Cancer 6, 204-216 (2006).
72. Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003).
73. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17, 163-169 (2005).
74. Bancherau J, Palucka K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306 (2005).
75. Pilla L, Valenti R, Marrari A et al. Vaccination: role in metastatic melanoma. Expert Rev. Anticancer Ther. 6, 1305-1318 (2006).
76. Conrad C, Nestle FO. Dendritic cell-based cancer therapy. Curr. Opin. Mol. Ther. 5, 405-412 (2003).
77. Delia Bella S, Nicola S, Riva A, Biasin M, Clerici M, Villa ML. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-α. J. Leukoc. Biol. 75, 106-116 (2004).
78. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004).
79. Kumamoto T, Huang EK, Paek HJ et al. Induction of tumor specific protective immunity by in situ Langerhans cell vaccine. Nat. Biotechnol. 20, 64-69 (2002).